NSE: PPLPHARMA
PIRAMAL PHARMA LIMITED
Price history
+31.02% over 3M
Performance
52-week range
Position in day range
PPLPHARMA stock DNA
Signals computed live from NSE price history — trend, momentum, volatility and participation in one view.
Trend
Uptrend
50-DMA ₹199.58
RSI (14)
50
Neutral momentum
Volatility (ATR)
3.41%
Moderate
Close streak
3d down
Volume vs 20d avg
0.77x
From 52W high
-8.87%
Up from 52W low
+59.75%
Green days (20)
9/20
Monthly seasonality
Average monthly move for PPLPHARMA across the available price history.
Key statistics
Open
210.59
Day high
214.45
Day low
208.68
Prev close
211.35
Volume
34.09 L
Avg vol (20d)
44.29 L
52W high
231.93
52W low
132.3
PPLPHARMA quarterly results
All PPLPHARMA results →Next results date
Awaiting intimation
Last results date
—
Reports published
Coverage coming soon
Revenue
₹2,270 cr
+17.4% YoY
Net profit
-₹69.39 cr
+15.1% YoY
Operating profit
-₹28.35 cr
+68.7% YoY
EPS
₹-0.52
+16.1% YoY
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q1 FY272026-06-30 | ₹2,270 cr | -₹28.35 cr | -₹69.39 cr | -1.2% | -3.1% | ₹-0.52 | +15.1% | -686.7% |
| Q4 FY262026-03-31 | ₹2,752 cr | ₹242 cr | -₹8.82 cr | 8.8% | -0.3% | ₹-0.07 | -105.7% | +93.5% |
| Q3 FY262025-12-31 | ₹2,140 cr | -₹17.01 cr | -₹136 cr | -0.8% | -6.4% | ₹-1.03 | — | -66.7% |
| Q1 FY262025-06-30 | ₹1,934 cr | -₹90.58 cr | -₹81.7 cr | -4.7% | -4.2% | ₹-0.62 | — | -153.2% |
| Q4 FY252025-03-31 | ₹2,754 cr | ₹318 cr | ₹154 cr | 11.6% | 5.6% | ₹1.16 | — | — |
| TTM (last 4 quarters) | ₹9,095 cr | ₹106 cr | -₹296 cr | 1.2% | -3.3% | ₹-2.24 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Latest coverage
Piramal Pharma Edges Lower to ₹211.35 — Should Investors Read This as a Trend or a One-Day Move?
Piramal Pharma (PPLPHARMA) trades at ₹211.35, -1.14 (-0.54%). The in-focus trigger, the levels the tape is defending, and what the numbers mean for traders and long-term holders.
Piramal Pharma Share Price Edges Lower to ₹211.35: What Is Driving PPLPHARMA Today, and the Levels That Matter
Piramal Pharma (PPLPHARMA) trades at ₹211.35, -1.14 (-0.54%). We read the exchange board, the volume against its own average, and what a shareholder should actually do with this information.
Latest market news
NATCAPSUQ in Focus: Natural Capsules Share Price Opens Gap-Up at ₹192.60 on Rising Newsflow
Natural Capsules (NATCAPSUQ) trades at ₹188.70, -2.04 (-1.08%) as the in-focus story plays out. Live board, day range, twelve-month context and the follow-up that decides the next session.
Technology And IT Leads the Morning Market Talk on 15 September 2026, Gold and Pharma And Healthcare Close Behind
The most-covered market themes in the morning session on 15 September 2026 — technology and IT, gold, pharma and healthcare — with our live numbers for each and links to the publishers running the story.
Solar Industries (I) Share Price Trades Flat at ₹22,290.00 Today — Volumes, 52-Week Range and What to Watch Next
Solar Industries (I) (SOLARINDS) trades at ₹22,290.00, -80.00 (-0.36%) as the in-focus story plays out. Live board, day range, twelve-month context and the follow-up that decides the next session.
Coforge Share Price Opens Gap-Down at ₹1,807.30 Today — Volumes, 52-Week Range and What to Watch Next
Coforge (COFORGE) trades at ₹1,846.50, +13.40 (+0.73%) as the in-focus story plays out. Live board, day range, twelve-month context and the follow-up that decides the next session.
Breaking: Nifty Tumbles 1.00% to 23,398.10 on 15 September 2026
The Nifty 50 is down 1.00% at 23,398.10 as of 12:00 am IST. Live breadth, sector damage and the biggest movers behind the move.
COFORGE in Focus: Coforge Share Price Opens Gap-Down at ₹1,807.30 on Rising Newsflow
Coforge (COFORGE) trades at ₹1,846.50, +13.40 (+0.73%). The in-focus trigger, the levels the tape is defending, and what the numbers mean for traders and long-term holders.
Price and history data from NSE via Upstox. For information only, not investment advice.